# A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Participants With Moderate to Severe Ulcerative Colitis (UC)

> **NCT06137183** · PHASE2 · TERMINATED · sponsor: **Genentech, Inc.** · enrollment: 79 (actual)

## Conditions studied

- Ulcerative Colitis

## Interventions

- **DRUG:** Vixarelimab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06137183
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2024-05-01
- **Primary completion:** 2025-06-16
- **Final completion:** 2025-06-16
- **Target enrollment:** 79 (ACTUAL)
- **Why stopped:** Based on a futility analysis, which suggested that the Moonglow study was unlikely to meet its primary endpoint.
- **Last updated:** 2026-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06137183

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06137183, "A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Participants With Moderate to Severe Ulcerative Colitis (UC)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06137183. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*